Essai Clinique

Généré le 29 avr. 2024 à partir de

Titre	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
Protocole ID	20170543 (CodeBreaK 100)
ClinicalTrials.gov ID	NCT03600883
Type(s) de cancer	Poumon non à petites cellules Tumeurs solides
Phase	Phase I-II
Type étude	Clinique
Médicament	AMG 510
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL H SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	
Investigateur principal	Dr Benjamin Shieh
Coordonnateur	Nicola Raby 514-934-1934 poste 34095
Statut	Fermé
But étude	Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Critères d'éligibilité	• Men or women greater than or equal to 18 years old. • Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.
Critères d'exclusion	• Active brain metastases from non-brain tumors. • Myocardial infarction within 6 months of study day 1. • Gastrointestinal (GI) tract disease causing the inability to take oral medication.